{"transactions":[{"id":832726,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-20T21:23:43.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":1800,"price":2.8,"value":5040.0,"ownership":{"direct":true},"balance_after":63656,"source":{"system":"sec-edgar","filing":"0001632384-26-000002","document":"wk-form4_1774041820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000163238426000002/wk-form4_1774041820.xml","form_type":"4"}},{"id":1201689,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:13:31.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":5.17,"value":5170.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock award will vest 100% on March 17, 2026."}],"balance_after":61856,"source":{"system":"sec-edgar","filing":"0001628280-25-013541","document":"wk-form4_1742332404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025013541/wk-form4_1742332404.xml","form_type":"4"}},{"id":1291105,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-30T21:39:44.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":1.71,"value":4275.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed solely to correct an administrative error in reporting the number of Securities  Acquired by Reporting Owner on the original Form 4 submitted on March 26, 2024, which were reported as 1,000 shares granted on March 25, 2024, but should have been reported as 2,500 shares.  This reflects an increase of 1,500 shares."}],"balance_after":60856,"source":{"system":"sec-edgar","filing":"0001628280-25-003185","document":"wk-form4a_1738273177.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025003185/wk-form4a_1738273177.xml","form_type":"4/A","original_submission_date":"2024-03-26"}},{"id":1561042,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-27T00:31:55.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":1.71,"value":1710.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock award will vest 100% on March 25, 2025."}],"balance_after":59356,"source":{"system":"sec-edgar","filing":"0001214659-24-005222","document":"marketforms-65375.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000121465924005222/marketforms-65375.xml","form_type":"4"}},{"id":1604043,"issuer":{"id":70624,"kind":"organization","name":"PINNACLE FINANCIAL PARTNERS INC","symbol":"PNFP"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"PNFP Common Stock","published_at":"2024-03-04T14:46:49.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves."}],"balance_after":24168,"source":{"system":"sec-edgar","filing":"0001115055-24-000054","document":"wk-form4_1709581599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1115055/000111505524000054/wk-form4_1709581599.xml","form_type":"4"}},{"id":1604042,"issuer":{"id":70624,"kind":"organization","name":"PINNACLE FINANCIAL PARTNERS INC","symbol":"PNFP"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"PNFP Common Stock","published_at":"2024-03-04T14:46:49.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":239,"price":82.72,"value":19770.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards."}],"balance_after":23179,"source":{"system":"sec-edgar","filing":"0001115055-24-000054","document":"wk-form4_1709581599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1115055/000111505524000054/wk-form4_1709581599.xml","form_type":"4"}},{"id":1938308,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T21:39:43.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":1.92,"value":1920.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock award will vest 100% on March 24, 2024."}],"balance_after":58356,"source":{"system":"sec-edgar","filing":"0001209191-23-021278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919123021278/doc4.xml","form_type":"4"}},{"id":1980449,"issuer":{"id":70624,"kind":"organization","name":"PINNACLE FINANCIAL PARTNERS INC","symbol":"PNFP"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"PNFP Common Stock","published_at":"2023-03-02T15:10:03.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":1084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares with restrictions that lapse on March 1, 2024 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves."}],"balance_after":23418,"source":{"system":"sec-edgar","filing":"0001567619-23-004174","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1115055/000156761923004174/doc1.xml","form_type":"4"}},{"id":1980448,"issuer":{"id":70624,"kind":"organization","name":"PINNACLE FINANCIAL PARTNERS INC","symbol":"PNFP"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"PNFP Common Stock","published_at":"2023-03-02T15:10:03.000Z","date":"2023-03-01","kind":"tax_withholding","acquired":false,"shares":174,"price":74.09,"value":12891.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards."}],"balance_after":22334,"source":{"system":"sec-edgar","filing":"0001567619-23-004174","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1115055/000156761923004174/doc1.xml","form_type":"4"}},{"id":2048847,"issuer":{"id":70624,"kind":"organization","name":"PINNACLE FINANCIAL PARTNERS INC","symbol":"PNFP"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"PNFP Common Stock","published_at":"2023-01-23T13:20:11.000Z","date":"2023-01-20","kind":"purchase","acquired":true,"shares":1000,"price":72.26,"value":72260.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $72.25 to $72.26. The reporting person undertakes to provide Pinnacle Financial Partners, Inc., any security holder of Pinnacle Financial Partners, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":22508,"source":{"system":"sec-edgar","filing":"0001567619-23-001121","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1115055/000156761923001121/doc1.xml","form_type":"4"}},{"id":2077083,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-21","kind":"purchase","acquired":true,"shares":180,"price":2.22,"value":399.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":57356,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077082,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-20","kind":"purchase","acquired":true,"shares":200,"price":2.31,"value":462.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":57176,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077081,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-19","kind":"purchase","acquired":true,"shares":250,"price":2.21,"value":552.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56976,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077080,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-16","kind":"purchase","acquired":true,"shares":100,"price":2.22,"value":222.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56726,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077079,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-15","kind":"purchase","acquired":true,"shares":60,"price":2.24,"value":134.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56626,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077078,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-14","kind":"purchase","acquired":true,"shares":120,"price":2.21,"value":265.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56566,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077077,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-13","kind":"purchase","acquired":true,"shares":120,"price":2.18,"value":261.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56446,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077076,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-12","kind":"purchase","acquired":true,"shares":65,"price":2.14,"value":139.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56326,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077075,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":65,"price":2.15,"value":139.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56261,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077074,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-08","kind":"purchase","acquired":true,"shares":65,"price":2.19,"value":142.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56196,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077073,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-07","kind":"purchase","acquired":true,"shares":65,"price":2.18,"value":141.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56131,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077072,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-06","kind":"purchase","acquired":true,"shares":65,"price":2.19,"value":142.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56066,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077071,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-05","kind":"purchase","acquired":true,"shares":65,"price":2.19,"value":142.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":56001,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077070,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-02","kind":"purchase","acquired":true,"shares":65,"price":2.31,"value":150.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55936,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077069,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:10:18.000Z","date":"2022-12-01","kind":"purchase","acquired":true,"shares":65,"price":2.33,"value":151.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55871,"source":{"system":"sec-edgar","filing":"0001209191-22-062651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062651/doc4.xml","form_type":"4"}},{"id":2077011,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-30","kind":"purchase","acquired":true,"shares":65,"price":2.32,"value":150.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55806,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077010,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-29","kind":"purchase","acquired":true,"shares":65,"price":2.34,"value":152.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55741,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077009,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-28","kind":"purchase","acquired":true,"shares":65,"price":2.37,"value":154.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55676,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077008,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":65,"price":2.31,"value":150.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55611,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077007,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-23","kind":"purchase","acquired":true,"shares":65,"price":2.29,"value":148.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55546,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077006,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":65,"price":2.37,"value":154.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55481,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077005,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-21","kind":"purchase","acquired":true,"shares":65,"price":2.38,"value":154.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55416,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077004,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":65,"price":2.27,"value":147.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55351,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077003,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-17","kind":"purchase","acquired":true,"shares":65,"price":2.29,"value":148.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55286,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077002,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-16","kind":"purchase","acquired":true,"shares":65,"price":2.31,"value":150.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55221,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077001,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-15","kind":"purchase","acquired":true,"shares":65,"price":2.35,"value":152.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55156,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2077000,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-14","kind":"purchase","acquired":true,"shares":65,"price":2.32,"value":150.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55091,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076999,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-11","kind":"purchase","acquired":true,"shares":65,"price":2.32,"value":150.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":55026,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076998,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-10","kind":"purchase","acquired":true,"shares":65,"price":2.37,"value":154.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54961,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076997,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-09","kind":"purchase","acquired":true,"shares":65,"price":2.37,"value":154.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54896,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076996,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-08","kind":"purchase","acquired":true,"shares":65,"price":2.42,"value":157.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54831,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076995,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-07","kind":"purchase","acquired":true,"shares":65,"price":2.45,"value":159.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54766,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076994,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-04","kind":"purchase","acquired":true,"shares":65,"price":2.42,"value":157.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54701,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076993,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-03","kind":"purchase","acquired":true,"shares":65,"price":2.44,"value":158.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54636,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076992,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-02","kind":"purchase","acquired":true,"shares":65,"price":2.54,"value":165.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54571,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2076991,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:03:07.000Z","date":"2022-11-01","kind":"purchase","acquired":true,"shares":65,"price":2.53,"value":164.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54506,"source":{"system":"sec-edgar","filing":"0001209191-22-062643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122062643/doc4.xml","form_type":"4"}},{"id":2110780,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-31","kind":"purchase","acquired":true,"shares":65,"price":2.54,"value":165.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54441,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110779,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-28","kind":"purchase","acquired":true,"shares":65,"price":2.52,"value":163.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54376,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110778,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-27","kind":"purchase","acquired":true,"shares":65,"price":2.49,"value":161.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54311,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110777,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-26","kind":"purchase","acquired":true,"shares":65,"price":2.42,"value":157.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54246,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110776,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-25","kind":"purchase","acquired":true,"shares":65,"price":2.44,"value":158.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54181,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110775,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-24","kind":"purchase","acquired":true,"shares":65,"price":2.38,"value":154.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54116,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110774,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-21","kind":"purchase","acquired":true,"shares":65,"price":2.49,"value":161.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":54051,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110773,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-20","kind":"purchase","acquired":true,"shares":65,"price":2.44,"value":158.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53986,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110772,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-19","kind":"purchase","acquired":true,"shares":65,"price":2.42,"value":157.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53921,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110771,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-18","kind":"purchase","acquired":true,"shares":65,"price":2.46,"value":159.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53856,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110770,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":65,"price":2.33,"value":151.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53791,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110769,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-14","kind":"purchase","acquired":true,"shares":65,"price":2.31,"value":150.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53726,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110768,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-13","kind":"purchase","acquired":true,"shares":65,"price":2.38,"value":154.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53661,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110767,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-12","kind":"purchase","acquired":true,"shares":65,"price":2.49,"value":161.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53596,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110766,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-11","kind":"purchase","acquired":true,"shares":65,"price":2.48,"value":161.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53531,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110765,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-10","kind":"purchase","acquired":true,"shares":65,"price":2.53,"value":164.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53466,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110764,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-07","kind":"purchase","acquired":true,"shares":65,"price":2.66,"value":172.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53401,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110763,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-06","kind":"purchase","acquired":true,"shares":65,"price":2.65,"value":172.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53336,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110762,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-05","kind":"purchase","acquired":true,"shares":65,"price":2.58,"value":167.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53271,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110761,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-04","kind":"purchase","acquired":true,"shares":65,"price":2.61,"value":169.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53206,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110760,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-10-03","kind":"purchase","acquired":true,"shares":65,"price":2.54,"value":165.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53141,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110759,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-09-30","kind":"purchase","acquired":true,"shares":65,"price":2.61,"value":169.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53076,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110758,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-09-29","kind":"purchase","acquired":true,"shares":65,"price":2.51,"value":163.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":53011,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110757,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":65,"price":2.52,"value":163.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52946,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2110756,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T22:17:54.000Z","date":"2022-09-27","kind":"purchase","acquired":true,"shares":65,"price":2.57,"value":167.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52881,"source":{"system":"sec-edgar","filing":"0001209191-22-057942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122057942/doc4.xml","form_type":"4"}},{"id":2148941,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-27","kind":"purchase","acquired":true,"shares":65,"price":2.57,"value":167.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52881,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148940,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-26","kind":"purchase","acquired":true,"shares":65,"price":2.49,"value":161.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52816,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148939,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-23","kind":"purchase","acquired":true,"shares":65,"price":2.55,"value":165.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52751,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148938,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-22","kind":"purchase","acquired":true,"shares":65,"price":2.51,"value":163.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52686,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148937,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-21","kind":"purchase","acquired":true,"shares":65,"price":2.59,"value":168.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52621,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148936,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-20","kind":"purchase","acquired":true,"shares":65,"price":2.54,"value":165.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52556,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148935,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-19","kind":"purchase","acquired":true,"shares":65,"price":2.56,"value":166.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52491,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148934,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":70,"price":2.49,"value":174.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52426,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148933,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-15","kind":"purchase","acquired":true,"shares":70,"price":2.47,"value":172.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52356,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148932,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":70,"price":2.51,"value":175.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52286,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148931,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-13","kind":"purchase","acquired":true,"shares":70,"price":2.45,"value":171.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52216,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148930,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-12","kind":"purchase","acquired":true,"shares":70,"price":2.46,"value":172.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52146,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148929,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-09","kind":"purchase","acquired":true,"shares":70,"price":2.21,"value":154.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52076,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148928,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":40,"price":2.22,"value":88.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":52036,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148927,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":70,"price":2.24,"value":156.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51966,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148926,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-06","kind":"purchase","acquired":true,"shares":70,"price":2.15,"value":150.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51896,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148925,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-02","kind":"purchase","acquired":true,"shares":70,"price":2.42,"value":169.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51826,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148924,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-09-01","kind":"purchase","acquired":true,"shares":70,"price":2.39,"value":167.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51756,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148923,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"shares":70,"price":2.36,"value":165.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51686,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148922,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-30","kind":"purchase","acquired":true,"shares":70,"price":2.38,"value":166.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51616,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148921,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":70,"price":2.44,"value":170.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51546,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148920,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":65,"price":2.55,"value":165.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51476,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148919,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-25","kind":"purchase","acquired":true,"shares":65,"price":2.62,"value":170.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51411,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148918,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-24","kind":"purchase","acquired":true,"shares":65,"price":2.59,"value":168.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51346,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148917,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-23","kind":"purchase","acquired":true,"shares":65,"price":2.59,"value":168.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51281,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148916,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-22","kind":"purchase","acquired":true,"shares":65,"price":2.51,"value":163.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51216,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148915,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-19","kind":"purchase","acquired":true,"shares":65,"price":2.35,"value":152.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51151,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148914,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-18","kind":"purchase","acquired":true,"shares":65,"price":2.23,"value":144.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51086,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}},{"id":2148913,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":56926,"kind":"person","name":"Galante Joseph C","position":1,"cik":"0001632384","reported_name":"Galante Joseph C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T21:13:45.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":65,"price":2.31,"value":150.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022."}],"balance_after":51021,"source":{"system":"sec-edgar","filing":"0001209191-22-051667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122051667/doc4.xml","form_type":"4"}}],"next_cursor":"2022-09-30T21:13:45.000000Z,2148913"}